Step closer to understanding childhood degenerative brain disease

July 3, 2012

(Medical Xpress) -- Researchers at the Australian Institute for Bioengineering and Nanotechnology (AIBN) are a step closer to understanding and combating the degenerative brain disease ataxia-telangiectasia.

As part of a collaborative project, Associate Professor Ernst Wolvetang's AIBN research group has reprogrammed, for the first time, from people with the disease so they can study the effectiveness of potential treatments.

The collaborators are from the Queensland Institute of Medical Research (QIMR) and The University of Queensland's Centre for Clinical Research (UQCCR) led by Professor Martin Lavin.

The reprogramming involves taking skin cells, generating and turning them into for study in the lab.

People with ataxia-telangiectasia develop cancer and brain degeneration because a gene that recognises and repairs is defective.

Associate Professor Wolvetang said the ability to reprogram skin cells from children with ataxia-telangiectasia provided a renewable resource to study the and find medicines to combat it.

“The next step is to correct the genetic mutations in the induced pluripotent stem cellsfrom these patients and then turn these corrected into brain and blood cells and demonstrate these can replace the defective cells that cause the problems in this disease,” Associate Professor Wolvetang said.

“Delivery of such corrected cells, which is still some years away, or novel drugs discovered using the cells generated in this study may help in treating this disease.”

The researchers could start screening medicines in one to two years, but testing in animals would have to be completed before they could be used in humans.

Professor Lavin said the research had benefited from combining his QIMR and UQCCR research group's expertise with that of Associate Professor Wolvetang's AIBN group.

“Joint PhD student Sam Nayler,the support of the patient advocate group BrAshAT, the National Health and Medical Research Council (NHMRC) and a private donor have been instrumental in the success of the project,” Professor Lavin said.

Ataxia-telangiectasia is a rare, inherited disease causing severe disability, including difficulty with movement and coordination, a weakened immune system, a predisposition to infection and a increasing the risk of cancer.

It affects between one in 100,000 and one in 300,000 people.

Patients are frequently in a wheelchair by their early teens and it is generally fatal by the time they reach their twenties.

“I have met patients and their families,” Associate Professor Wolvetang said.

“Witnessing the determination of the children to live life to the full and the heartache borne by their parents, it is self-evident that every effort must be expended to treat these rare diseases.”

The establishment of an Ataxia-telangiectasia Clinic by Dr Kate Sinclair and colleagues at the Royal Children's Hospital and UQCCR has been a great benefit to patient management and for the conduct of these studies.

Details of the skin cell reprogramming from ataxia telangiectasia patients have been published in the journal Stem Translational Medicine.

Explore further: Researchers make breakthrough in stem cell research

More information: View the online publication at

Related Stories

Researchers make breakthrough in stem cell research

February 13, 2012

(Medical Xpress) -- University of Queensland scientists have developed a world-first method for producing adult stem cells that will substantially impact patients who have a range of serious diseases.

Researchers decode a puzzling movement disorder

November 25, 2011

Neurodegenerative diseases represent one of the greatest challenges of our aging society. However, investigation into these diseases is made particularly difficult due to the limited availability of human brain tissue. Scientists ...

Recommended for you

Rac1 protein critical for lung development

October 20, 2016

A study by researchers from The Saban Research Institute of Children's Hospital Los Angeles reveals a promising therapeutic target for improving lung function in infants. Their study, now published online by the American ...

A vitamin could help treat Duchenne muscular dystrophy

October 19, 2016

Duchenne is the most common and severe form of muscular dystrophy. Because of this genetic disease, one out of every 3,500 children spends their 12th birthday in a wheelchair. This disorder progressively leads to general ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.